UroGen Pharma to Present at Upcoming Investor Conferences

PRINCETON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in the following investor conferences in May.

The webcasts from the conference will also be available on UroGen’s Investor Relations website. A replay will be available for approximately 90 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first product to treat LG-UTUC and second product (mitomycin) for intravesical solution for adults with recurrent LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on X, @UroGenPharma.

INVESTORS:

Vincent Perrone
Senior Director, Investor Relations
[email protected]
609-460-3588 ext. 1093

MEDIA:

Cindy Romano
Director, Corporate Communications
[email protected]
609-460-3566 ext. 1083

You May Also Be Interested In

• H.C. Wainwright Reiterates Buy Rating on UroGen Pharma (URGN)
• Amid Declining Book Value, ACRES Commercial Realty Struggles to Sell REO Property Due to Labor Dispute with Philadelphia Hospitality Union UNITE HERE Local 274
• Tuscan-Inspired Estate in Appalachian Wine Country Comes to Market for $7.9 Million